240 Chapter 11 Table 1. Continued Reference Year Country Study Design Patient Inclusion Period Reasons for Patient Exclusion No. of Subjects No. of Genes Investigated Aim of the Study Start End Smith et al. 37 2013 UK CH - - Patients with resectable disease. 2161 4 To study the somatic molecular profile of the epidermal growth factor receptor pathway in advanced CRC, its relationship to prognosis, the site of the primary and metastases, and response to cetuximab. Takahashi et al. 38 2013 Japan CH 1992 2002 - 180 1 To investigate the clinical significance of NEK2/miR128 expression in CRC. Taniguchi et al. 39 2020 Japan CH 08/2014 04/2016 RAS-mutant tumors or unknown RAS status. 331 2 To present institutional experience with patients with CRC who underwent clinical mutation profiling and to evaluate the differences in patient characteristics with BRAF mutations. Tran et al. 48 2011 Australia CH - - - 524 1 To investigate whether BRAF mutant CRC is further defined by metastatic spread and evaluation of the impact of this mutation on prognosis. Yaeger et al. 49 2014 USA CC 2009 2012 - 515 1 To determine the clinicopathologic characteristics, PIK3CA mutation frequency, and outcomes after metastasectomy in patients with BRAF-mutant mCRC.
RkJQdWJsaXNoZXIy MTk4NDMw